| Product Code: ETC7623316 | Publication Date: Sep 2024 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Ireland Antisense and RNAi Therapeutics Market Overview |
3.1 Ireland Country Macro Economic Indicators |
3.2 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, 2021 & 2031F |
3.3 Ireland Antisense and RNAi Therapeutics Market - Industry Life Cycle |
3.4 Ireland Antisense and RNAi Therapeutics Market - Porter's Five Forces |
3.5 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.6 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume Share, By Technology, 2021 & 2031F |
3.7 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume Share, By End Users, 2021 & 2031F |
3.9 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Ireland Antisense and RNAi Therapeutics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of genetic disorders in Ireland |
4.2.2 Growing research and development activities in the field of antisense and RNAi therapeutics |
4.2.3 Favorable government initiatives and funding for advanced healthcare technologies |
4.3 Market Restraints |
4.3.1 Stringent regulatory approval processes for new therapeutics |
4.3.2 High costs associated with development and commercialization of antisense and RNAi therapies |
4.3.3 Limited awareness and adoption of these advanced therapies among healthcare providers and patients in Ireland |
5 Ireland Antisense and RNAi Therapeutics Market Trends |
6 Ireland Antisense and RNAi Therapeutics Market, By Types |
6.1 Ireland Antisense and RNAi Therapeutics Market, By Indication |
6.1.1 Overview and Analysis |
6.1.2 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By Indication, 2021- 2031F |
6.1.3 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By Oncology, 2021- 2031F |
6.1.4 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By Cardiovascular Diseases (CVDs), 2021- 2031F |
6.1.5 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By Respiratory Disorders, 2021- 2031F |
6.1.6 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By Neurological Disorders, 2021- 2031F |
6.1.7 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By Infectious Diseases, 2021- 2031F |
6.1.8 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Ireland Antisense and RNAi Therapeutics Market, By Technology |
6.2.1 Overview and Analysis |
6.2.2 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By RNA Interference, 2021- 2031F |
6.2.3 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By Antisense RNA, 2021- 2031F |
6.3 Ireland Antisense and RNAi Therapeutics Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By Pulmonary Delivery, 2021- 2031F |
6.3.3 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By Intravenous Injections, 2021- 2031F |
6.3.4 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By Intra-Dermal, 2021- 2031F |
6.3.5 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By Intraperitoneal, 2021- 2031F |
6.3.6 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By Topical, 2021- 2031F |
6.3.7 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Ireland Antisense and RNAi Therapeutics Market, By End Users |
6.4.1 Overview and Analysis |
6.4.2 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.4 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Ireland Antisense and RNAi Therapeutics Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.5.4 Ireland Antisense and RNAi Therapeutics Market Revenues & Volume, By Others, 2021- 2031F |
7 Ireland Antisense and RNAi Therapeutics Market Import-Export Trade Statistics |
7.1 Ireland Antisense and RNAi Therapeutics Market Export to Major Countries |
7.2 Ireland Antisense and RNAi Therapeutics Market Imports from Major Countries |
8 Ireland Antisense and RNAi Therapeutics Market Key Performance Indicators |
8.1 Number of clinical trials and research studies related to antisense and RNAi therapeutics in Ireland |
8.2 Adoption rate of antisense and RNAi therapies in healthcare facilities |
8.3 Rate of increase in investments and funding for antisense and RNAi therapeutic development in Ireland |
9 Ireland Antisense and RNAi Therapeutics Market - Opportunity Assessment |
9.1 Ireland Antisense and RNAi Therapeutics Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.2 Ireland Antisense and RNAi Therapeutics Market Opportunity Assessment, By Technology, 2021 & 2031F |
9.3 Ireland Antisense and RNAi Therapeutics Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 Ireland Antisense and RNAi Therapeutics Market Opportunity Assessment, By End Users, 2021 & 2031F |
9.5 Ireland Antisense and RNAi Therapeutics Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Ireland Antisense and RNAi Therapeutics Market - Competitive Landscape |
10.1 Ireland Antisense and RNAi Therapeutics Market Revenue Share, By Companies, 2024 |
10.2 Ireland Antisense and RNAi Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here